View More Recent Stories
-
Replimune Group, Inc. (REPL) Tops Q2 EPS by 14c
-
H.C. Wainwright Reiterates Buy Rating on Replimune Group (REPL)
-
BMO Capital Reiterates Outperform Rating on Replimune Group (REPL)
-
H.C. Wainwright Reiterates Buy Rating on Replimune Group (REPL)
-
Roth/MKM Reiterates Buy Rating on Replimune Group (REPL)
-
Replimune (REPL) Reports Positive Pre-BLA Meeting with FDA and Confirms BLA Submission On Track for 2H 2024
-
Replimune (REPL): Stockholders Vote to Elect Madhavan Balachandran to Board of Directors
-
Roth/MKM Starts Replimune Group (REPL) at Buy
-
Replimune (REPL) Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma
-
Replimune Group, Inc. (REPL) Tops Q1 EPS by 8c
-
Replimune (REPL) Announces $100 Million Private Placement Financing

